Literature DB >> 19784818

Long-term prognostic value of coronary flow velocity reserve in patients with hypertrophic cardiomyopathy: 9-year follow-up results from SZEGED study.

Attila Nemes1, Erika Balázs, Osama I I Soliman, Róbert Sepp, Miklós Csanády, Tamás Forster.   

Abstract

Reduction in coronary flow velocity reserve (CFR) is a recognized feature in hypertrophic cardiomyopathy (HCM). We sought to assess the long-term prognostic value of CFR by pulsed-wave Doppler transesophageal echocardiography (TEE) in HCM patients. The study comprised 20 patients with typical features of HCM. The patients were enrolled in 1999. All patients underwent a standard transthoracic echo-Doppler study to evaluate left ventricular function and a stress vasodilator TEE study to evaluate CFR. The success rate of follow-up was 18 out of 20 (90%). During a mean follow-up of 90 +/- 24 months, four patients suffered cardiovascular death (2 sudden cardiac deaths and 2 strokes). The other seven patients underwent invasive procedures (coronary angiography, implantable cardioverter defibrillator implantation, percutaneous transluminal septal myocardial ablation) or showed cerebrovascular events. Using receiver operator characteristic analysis, CFR < 2.35 was a significant predictor for cardiovascular event-free survival (sensitivity 91%, specificity 71%, area under the curve 74%, P = 0.05). Multivariable regression analysis showed that only CFR (hazard ratio (HR) 4.21, P < 0.05) was an independent predictor of cardiovascular event-free survival. Despite the relatively small number of patients involved in the study, results could suggest that CFR should be considered as an independent predictor for future cardiovascular events in HCM patients. However, further studies with larger HCM patient populations are warranted.

Entities:  

Mesh:

Year:  2009        PMID: 19784818     DOI: 10.1007/s00380-008-1131-0

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  25 in total

1.  Assessment of coronary flow reserve with transthoracic Doppler echocardiography: comparison among adenosine, standard-dose dipyridamole, and high-dose dipyridamole.

Authors:  H E Lim; W J Shim; H Rhee; S M Kim; G S Hwang; Y H Kim; H S Seo; D J Oh; Y M Ro
Journal:  J Am Soc Echocardiogr       Date:  2000-04       Impact factor: 5.251

Review 2.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

3.  Prognostic value of coronary flow reserve and aortic distensibility indices in patients with suspected coronary artery disease.

Authors:  Attila Nemes; Tamás Forster; Marcel L Geleijnse; Osama I I Soliman; Folkert J Ten Cate; Miklós Csanády
Journal:  Heart Vessels       Date:  2008-05-17       Impact factor: 2.037

4.  Coronary flow velocity pattern and coronary flow reserve by contrast-enhanced transthoracic echocardiography predict long-term outcome in heart transplantation.

Authors:  Francesco Tona; Alida L P Caforio; Roberta Montisci; Antonio Gambino; Annalisa Angelini; Massimo Ruscazio; Giuseppe Toscano; Giuseppe Feltrin; Angelo Ramondo; Gino Gerosa; Sabino Iliceto
Journal:  Circulation       Date:  2006-07-04       Impact factor: 29.690

5.  The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study.

Authors:  David W Dunstan; Paul Z Zimmet; Timothy A Welborn; Maximilian P De Courten; Adrian J Cameron; Richard A Sicree; Terry Dwyer; Stephen Colagiuri; Damien Jolley; Matthew Knuiman; Robert Atkins; Jonathan E Shaw
Journal:  Diabetes Care       Date:  2002-05       Impact factor: 19.112

6.  Assessment of intravascular and extravascular mechanisms of myocardial perfusion abnormalities in obstructive hypertrophic cardiomyopathy by myocardial contrast echocardiography.

Authors:  Osama I I Soliman; Paul Knaapen; Marcel L Geleijnse; Pieter A Dijkmans; Ashraf M Anwar; Attila Nemes; Michelle Michels; Wim B Vletter; Adriaan A Lammertsma; Folkert J ten Cate
Journal:  Heart       Date:  2007-05-08       Impact factor: 5.994

7.  Transesophageal Doppler echocardiography evaluation of coronary blood flow velocity in baseline conditions and during dipyridamole-induced coronary vasodilation.

Authors:  S Iliceto; V Marangelli; C Memmola; P Rizzon
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

8.  Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy.

Authors:  Osama I I Soliman; Marcel L Geleijnse; Michelle Michels; Pieter A Dijkmans; Attila Nemes; Bas M van Dalen; Wim B Vletter; Patrick W Serruys; Folkert J ten Cate
Journal:  Am J Cardiol       Date:  2008-03-17       Impact factor: 2.778

9.  The prognostic impact of coronary flow-reserve assessed by Doppler echocardiography in non-ischaemic dilated cardiomyopathy.

Authors:  Fausto Rigo; Sonia Gherardi; Maurizio Galderisi; Lorenza Pratali; Lauro Cortigiani; Rosa Sicari; Eugenio Picano
Journal:  Eur Heart J       Date:  2006-02-07       Impact factor: 29.983

10.  Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Iacopo Olivotto; Franco Cecchi; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Francesca Girolami; Francesca Torricelli; Paolo G Camici
Journal:  J Am Coll Cardiol       Date:  2006-03-07       Impact factor: 24.094

View more
  1 in total

1.  Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis.

Authors:  Qun Liu; Diandian Li; Alan E Berger; Roger A Johns; Li Gao
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.